UNSPSC 51263111: Bornaprolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66STS87GEY. European Medicines Agency schedules Bornaprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05875MIG. Bornaprolol generally arises in the molecular formula C19H29NO2. The term BORNAPROLOL is an International Non-Proprietary Name or INN. BORNAPROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule bornaprolol under HS 29221980 and SITC 51461. As of Q4 2014, BORNAPROLOL remains the US FDA Preferred Term for this commodity. Bornaprolol bears US NLM identifiers UMLS ID C0106915 and NCI Concept Code C90794. SMILES: O(C1C(C2C3CC(C2)CC3)CCCC1)CC(O)CNC(C)C.

UNSPSC 51263111 Bornaprolol is a Commodity code that does not reflect the work actually being solicited under it in recent state and local opportunities. The code's nominal scope — a specific pharmaceutical compound — bears no relationship to the naloxone procurement and direct-to-manufacturer prescription program intelligence gathering that appear in the recent opportunities block. Bornaprolol itself does not appear in either solicitation, and the opportunities posted under this code are fundamentally misaligned with the code's stated product. State and local procurement systems occasionally tag opportunities with codes that do not match the goods or services being bought, and this code shows little relevant recent activity when the actual solicitations are examined against the code's pharmaceutical scope.

The two opportunities on record — Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023) and the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (response deadline April 3, 2026) — involve naloxone supply and pharmaceutical distribution strategy, not bornaprolol procurement. Given the mismatch between code and content, firms evaluating this code should verify the actual UNSPSC classifications assigned to pharmaceutical procurements of interest rather than rely on the nominal taxonomy structure in this instance.